Regeneron Pharma Q4 Results Top Estimates - Update

RTTNews | 971 hari yang lalu
Stocktwits
Regeneron Pharma Q4 Results Top Estimates - Update

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter $1.37 billion or $11.86 per share, compared to $1.45 billion or $12.56 per share in the year-ago quarter.

On average, 21 analysts polled by Thomson Reuters expected the company to report earnings of $10.87 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter edged up 1 percent to $3.43 billion from $3.41 billion in the same quarter last year. Excluding Ronapreve, revenue grew 14 percent. Analysts were looking for revenues of $3.29 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Tag: REGN
Stocktwits
baca selengkapnya
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | 790 hari yang lalu
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews | 824 hari yang lalu
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | 1552 hari yang lalu
Canadian Market Headed For Another Weak Close

Canadian Market Headed For Another Weak Close

After opening marginally higher and advancing a bit further, the Canadian market turned weak on Wednesday as investors stayed cautious amid uncertainty about U.S. and Iran reaching a peace deal.
RTTNews | 34 menit yang lalu
Swiss Market Ends On Weak Note

Swiss Market Ends On Weak Note

The Switzerland stock market pared early gains and closed on a negative note on Wednesday as weak investor sentiment data and higher oil prices weighed.
RTTNews | 1 jam 15 menit yang lalu
European Markets Close Weak On Higher Oil Prices, U.S.-Iran Deal Uncertainty

European Markets Close Weak On Higher Oil Prices, U.S.-Iran Deal Uncertainty

European stocks fell on Wednesday, hurt by higher bond yields and rising oil prices amid lingering uncertainty about Iran and the U.S. reaching a deal to end their conflict and pave the way for the reopening of the Strait of Hormuz. Some weak economic data from the region - UK GDP report being an exception - weighed as well on sentiment.
RTTNews | 1 jam 43 menit yang lalu
Chicago Business Barometer Surges Back Into Expansionary Territory In September

Chicago Business Barometer Surges Back Into Expansionary Territory In September

A report released by MNI Indicators on Wednesday showed a substantial rebound by its reading on Chicago-area business activity in the month of September. MNI Indicators said its Chicago business barometer spiked to 58.8 in September from 47.1 in August, with a reading above 50 indicating growth. Economists had expected the index to jump to 51.0.
RTTNews | 5 jam 9 menit yang lalu
Perangkat
Kalender Ekonomi
Jam pasar
Suku bunga
Kalender hari libur
Pasar Valas
Volatilitas Forex
Korelasi Forex
Berita Forex
Analisis Forex
Data COT
Likuiditas
Kalkulator Forex
Peta Panas Forex
Indikator ekonomi Konverter mata uang
Komunitas
Komunitas
Sistems
Sistem Paling Populer
Strategi
Kontes
Grafik Forex
Sentimen Forex
Indikator Sentimen
Reviu
Pialang
Perusahaan Prop Trading
Layanan VPS
Penyedia Sinyal
Layanan Pemrograman EA
Program Afiliasi
Layanan Broker PAMM
Layanan Program Rebate
Platform Trading
Expert Advisor
Bursa Kripto
Kursus trading
Pelacak Portofolio Saham
Pialang
Spread Forex
Kutipan Broker Forex
Swap Broker Forex
Volume Broker Forex
Promosi Broker Forex
Siaran Pers
Platform
Widget
Fitur
API
RSS
Stock Portfolio
Affiliate Software
Grafik Lanjutan
Dukungan
FAQ
Bantuan
Hubungi Kami
Laporkan Bug!
Tentang
Blog
© 2026 Myfxbook Ltd. Hak Cipta Dilindungi.
PERINGATAN RISIKO TINGGI: Perdagangan valuta asing memiliki tingkat risiko tinggi yang mungkin tidak sesuai untuk semua investor. Leverage meningkatkan risiko dan potensi kerugian. Sebelum memutuskan untuk trading forex, pertimbangkan dengan saksama tujuan investasi, tingkat pengalaman, dan toleransi risiko Anda. Anda dapat kehilangan sebagian atau seluruh investasi awal Anda. Jangan investasikan uang yang tidak sanggup Anda tanggung kehilangannya. Pelajari risiko yang terkait dengan trading forex dan mintalah saran dari penasihat keuangan atau pajak independen jika Anda memiliki pertanyaan. Semua data dan informasi disediakan 'apa adanya' semata-mata untuk tujuan informasi, dan tidak dimaksudkan untuk tujuan perdagangan atau sebagai nasihat. Kinerja masa lalu bukan merupakan indikasi hasil di masa mendatang.